Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Identification and validation of diagnostic alternative splicing events in tumor-educated platelets for non-small cell lung cancer in patients with ground-glass opacity: a multicenter study

Title: Identification and validation of diagnostic alternative splicing events in tumor-educated platelets for non-small cell lung cancer in patients with ground-glass opacity: a multicenter study
Authors: Shao M.; Li W.; Cao J.; Wang L.; Xie S.; Hu Y.; Feng G.; Azari F.; Bertolaccini L.; Liu W.; He B.
Contributors: M. Shao; W. Li; J. Cao; L. Wang; S. Xie; Y. Hu; G. Feng; F. Azari; L. Bertolaccini; W. Liu; B. He
Publisher Information: AME Publishing Company
Publication Year: 2025
Collection: The University of Milan: Archivio Istituzionale della Ricerca (AIR)
Subject Terms: alternative splicing (AS); diagnostic marker; ground-glass opacities (GGOs); non-small cell lung cancer (NSCLC); Tumor-educated platelets (TEPs); Settore MEDS-13/A - Chirurgia toracica
Description: Background: The diagnostic potential of tumor-educated platelets (TEPs) across various cancer types has gained increasing recognition; however, the relationship between alternative splicing (AS) events in TEPs and tumor development remains understudied. Early detection of non-small cell lung cancer (NSCLC) in ground-glass opacities (GGOs) is critical for improving patient outcomes, yet current methods lack sufficient accuracy. Our research identified diagnostic-related alternative splicing events (DASEs) in TEPs, revealing several promising biomarkers for NSCLC, specifically in patients presenting with GGOs. Methods: Patients with GGOs from two hospitals were prospectively enrolled [Hospital 1-Platelet (H1- P) and Hospital 2-Tissue (H2-T) in the validation cohort; Hospital 2-Platelet (H2-P) in the test cohort]. Benign/malignant diagnosis of GGOs was confirmed by pathological examination according to the World Health Organization (WHO) classification. TEPs from the H1-P cohort were collected for transcriptome sequencing and AS analysis. Chi-square tests, least absolute shrinkage and selection operator (LASSO) regression analysis, and protein-protein interaction (PPI) network were used for the preliminary screening of DASEs. Pathological tissue from the H2-T cohort was collected to validate the diagnostic efficacy of hub DASEs in NSCLC against the pathological gold standard. Moreover, TEPs from the H2-P cohort were used to assess the predictive performance of hub DASEs for GGOs using receiver operating characteristic (ROC) curves. Decision curve analysis (DCA) was used to determine whether diagnosing NSCLC in the GGOs population via hub DASEs could benefit patients. Results: A total of 285 patients with GGOs were enrolled, including 151 NSCLC and 128 inflammatory nodules confirmed by pathological examination. Thirteen DASEs were screened with the chi-square test and LASSO regression analysis to identify diagnostic TEP AS markers for GGOs NSCLC. The PPI network identified four hub diagnostic-related alternative ...
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:001493778100023; volume:14; issue:4; firstpage:1395; lastpage:1407; numberofpages:13; journal:TRANSLATIONAL LUNG CANCER RESEARCH; https://hdl.handle.net/2434/1195861
DOI: 10.21037/tlcr-2025-287
Availability: https://hdl.handle.net/2434/1195861; https://doi.org/10.21037/tlcr-2025-287
Rights: info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.D5D6DC69
Database: BASE